Kangpu Biopharma receives China NMPA’s IND approval for KPG-818 to treat relapsed/refractory multiple myeloma: Hefei, China Saturday, March 1, 2025, 14:00 Hrs [IST] Kangpu Bioph ...
Regeneron Pharmaceuticals (NASDAQ:REGN) said the European Medicines Agency’s Committee for Medicinal Products for Human Use ...
After being diagnosed with multiple myeloma, Valarie Traynham turned her journey into a mission—raising awareness, educating ...
Janssen-Cilag International NV, a Johnson & Johnson company (NYSE:JNJ) announced Friday that an expert panel of the EU drug ...
Breast cancer and basal cell carcinoma were the most prevalent malignancies in patients with MS undergoing long-term DMT treatment.
Panelists discuss how to identify, monitor, and manage delayed toxicities following ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor (CAR) T therapy, including prolonged cytopenias, ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...
SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, and inflammatory and infectious diseases, announces the publication of ...
21h
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...
Discover how ctDNA revolutionizes multiple myeloma monitoring, tracking disease progression, and improving personalized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback